Cargando…

Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial

While therapies such as chemotherapy combined with immunotherapy, sacituzumab govitecan, and PARP inhibitors are available for metastatic TNBC, on disease progression after these therapies, the mainstay of therapy is chemotherapy. Apatinib is a small-molecule tyrosine kinase inhibitor that has promi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dou-Dou, Tao, Zhong-hua, Wang, Bi-Yun, Wang, Lei-Ping, Cao, Jun, Hu, Xi-Chun, Zhang, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489776/ https://www.ncbi.nlm.nih.gov/pubmed/36127351 http://dx.doi.org/10.1038/s41523-022-00462-6

Ejemplares similares

Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial
por: Wu, Shuo, et al.
Publicado: (2020)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Responses to docetaxel plus vinorelbine in metastatic breast cancer patients failing high-dose chemotherapy
por: Andres, R, et al.
Publicado: (2002)

Oral vinorelbine versus intravenous vinorelbine, in combination with epirubicin as first-line chemotherapy in Chinese patients with metastatic breast cancer
por: Huang, Liang, et al.
Publicado: (2019)

Oral vinorelbine in metastatic breast cancer
por: Conte, PF, et al.
Publicado: (2005)

Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy
por: Wang, Yue-shen, et al.
Publicado: (2016)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Vinorelbine induced perforation of a metastatic gastric lesion
por: Mullally, W. J., et al.
Publicado: (2016)

Vinorelbine – a clinical review
por: Gregory, R K, et al.
Publicado: (2000)

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
por: Zhang, Xiangyu, et al.
Publicado: (2020)

Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA
por: Zhu, Anjie, et al.
Publicado: (2021)

Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial
por: Babiak, A, et al.
Publicado: (2007)

Successful Concurrent Chemoradiotherapy with Cisplatin plus Vinorelbine for Locally Advanced Thymic Carcinoma
por: Fukushima, Toshirou, et al.
Publicado: (2014)

Comparison of Doxorubicin Plus Docetaxel Neoadjuvant Chemotherapy with Doxorubicin Plus Vinorelbine in Primary Breast Cancer
por: Gwak, Geumhee, et al.
Publicado: (2011)

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial
por: De Maio, Ermelinda, et al.
Publicado: (2007)

A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
por: Iaffaioli, R. V., et al.
Publicado: (1995)

Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer
por: Beretta, G D, et al.
Publicado: (2000)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
por: Valerio, Maria Rosaria, et al.
Publicado: (2021)

N-acetylcysteine attenuates the incidence of phlebitis induced by carbomer/vinorelbine gel
por: Zhang, Hongyu, et al.
Publicado: (2023)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
por: Chew, Helen Kent, et al.
Publicado: (2014)

Aspirin attenuates YAP and β-catenin expression by promoting β-TrCP to overcome docetaxel and vinorelbine resistance in triple-negative breast cancer
por: Ma, Ji, et al.
Publicado: (2020)

Carboplatin/vinorelbine: Worsening of lung adenocarcinoma: case report
Publicado: (2022)

Cisplatin plus vinorelbine as induction treatment in stage IIIA non-small cell lung cancer
por: Palka, Magda, et al.
Publicado: (2017)

Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
por: Stravodimou, Athina, et al.
Publicado: (2014)

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer
por: Ferrario, Cristiano, et al.
Publicado: (2016)

Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
por: Chan, A, et al.
Publicado: (2006)

Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study
por: Serin, D, et al.
Publicado: (2005)

Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
por: Stemmler, H J, et al.
Publicado: (2011)

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
por: Fløtten, Ø, et al.
Publicado: (2012)

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
por: Xie, Yizhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_t1l04creemf8f3fnrvbe3tubtc